Vertex Pharmaceuticals Inc
VRTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000875320
In the last 90 days, Vertex Pharmaceuticals Inc insiders filed 0 open-market purchases and 3 sales; 1,763 institutions reported holding it in 13F filings for Q2 2026, worth $119.7B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Vertex Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 3 filings
- 3 insiders, $2.00M in total
- Insiders trading
- 3
- Net value
- −$2.00M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Vertex Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| van Grunsven Jasper | EVP, CP and NPPO | 8,682 | Sep 10, 2026 | 1 |
| Ambrose Kristen | SVP & Chief Accounting Officer | 11,624 | Sep 1, 2026 | 7 |
| Sachs Bruce I | Director | 39,000 | Aug 31, 2026 | 6 |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | 53,572 | Jul 23, 2026 | 9 |
| Sachdev Amit | EVP Chief Patient & Ext Af Off | 66,512 | Jul 23, 2026 | 7 |
| Garber Alan M | Director | 7,344 | Jul 17, 2026 | 3 |
| McKechnie Duncan | EVP, Chief Commercial Officer | 11,001 | Jul 7, 2026 | 8 |
| Liu Joy | EVP and Chief Legal Officer | 19,131 | Jul 6, 2026 | 5 |
| Bozic Carmen | EVP and CMO | 15,337 | Jun 30, 2026 | 15 |
| Bunnage Mark E. | EVP, Chief Scientific Officer | 7,284 | May 19, 2026 | 5 |
| Carney Lloyd | Director | 6,315 | May 5, 2026 | 2 |
| Lagarde Michel | Director | 1,132 | May 5, 2026 | 1 |
| Upadhyay Suketu | Director | 1,558 | May 5, 2026 | 4 |
| Bhatia Sangeeta N. | Director | 4,924 | May 5, 2026 | 2 |
| McKenzie Diana | Director | 2,378 | May 5, 2026 | 1 |
| Schneider Jennifer | Director | 1,394 | May 5, 2026 | 1 |
| Thornberry Nancy | Director | 2,109 | May 5, 2026 | 1 |
| Kewalramani Reshma | CEO & President | 98,278 | Mar 3, 2026 | 6 |
| Wagner Charles F Jr | EVP, CO & FO | 47,042 | Feb 26, 2026 | 7 |
| Leiden Jeffrey M | Executive Chairman | 34,797 | Feb 26, 2026 | 5 |
| Biller Jonathan | EVP and Chief Legal Officer | 13,659 | Feb 26, 2026 | 7 |
| Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | 18,432 | Feb 26, 2026 | 6 |
| Altshuler David | EVP, Chief Scientific Officer | 34,477 | Jan 26, 2026 | 1 |
| Arbuckle Stuart A | EVP, COO | 63,368 | Jul 2, 2025 | 0 |
| Kearney Terrence C | Director | 6,536 | May 3, 2024 | 0 |
| Sanna Bastiano | EVP, Cell & Genetic Therapies | 32,038 | May 9, 2023 | 0 |
| McGlynn Margaret G | Director | 178 | May 3, 2023 | 0 |
| Lee Yuchun | Director | 1,875 | May 3, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 22, 2022 (view filing) | Feb 18 | 4 days | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | SSale | −519 | $231.00 | −$119.9K | −1.0%53.1K after | 4 lots |
| Feb 22, 2022 (view filing) | Feb 18 | 4 days | Altshuler DavidEVP, Global Research and CSO | SSale | −4.31K | $230.97 | −$995.9K | −8.0%49.7K after | 5 lots |
| Feb 16, 2022 (view filing) | Feb 14 | 2 days | Altshuler DavidEVP, Global Research and CSO | SSale | −2.44K | $232.02 | −$567.1K | −4.1%57.4K after | |
| Feb 14, 2022 (view filing) | Feb 11 | 3 days | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | SSale | −290 | $235.09 | −$68.2K | −0.5%57.7K after | 4 lots |
| Feb 14, 2022 (view filing) | Feb 11 | 3 days | Altshuler DavidEVP, Global Research and CSO | SSale | −2.30K | $235.02 | −$539.8K | −3.7%59.9K after | 4 lots |
| Feb 3, 2022 (view filing) | Feb 2 | 1 day | Wagner Charles F JrEVP & Chief Financial Officer | SSale | −2.94K | $250.07 | −$736.2K | −4.9%57.4K after | |
| Feb 3, 2022 (view filing) | Feb 2 | 1 day | Sanna BastianoEVP, Cell & Genetic Therapies | SSale | −1.04K | $250.98 | −$261.0K | −1.9%55.0K after | 5 lots |
| Feb 3, 2022 (view filing) | Feb 2 | 1 day | Altshuler DavidEVP, Global Research and CSO | SSale | −4.66K | $251.47 | −$1.17M | −6.6%65.7K after | 7 lots |
| Feb 1, 2022 (view filing) | Jan 28 | 4 days | McGlynn Margaret GDirector | SSale | −5.00K | $241.79 | −$1.21M | −82.0%1.10K after | 4 lots |
| Nov 16, 2021 (view filing) | Nov 15 | 1 day | Sachdev AmitEVP, Chief Patient Officer | SSale | −51 | $187.19 | −$9.55K | −0.2%31.9K after | 2 lots |
| Nov 16, 2021 (view filing) | Nov 15 | 1 day | Arbuckle Stuart AEVP, COO | SSale | −3 | $187.26 | −$561.78 | 0.0%41.1K after | 2 lots |
| Nov 16, 2021 (view filing) | Nov 15 | 1 day | Altshuler DavidEVP, Global Research and CSO | SSale | −34 | $187.22 | −$6.37K | −0.1%33.6K after | 2 lots |
| Aug 23, 2021 (view filing) | Aug 19 | 4 days | Kewalramani ReshmaCEO & President | PPurchase | +10.0K | $195.65 | +$1.96M | +15.7%73.8K after | 2 lots |
| Aug 4, 2021 (view filing) | Aug 2 | 2 days | Sachs Bruce IDirector | PPurchase | +15.0K | $197.91 | +$2.97M | +57.2%41.2K after |